Generic Versions of Biologics: The Problem and a Possible Solution By Paul F. Prestia This article is reprinted with permission from The Legal Intelligencer. © 2008 ALM Properties Inc. Further duplication without permis

First Page		Document Content
Date: 2013-03-31 19:00:47 Pharmaceuticals policy Pharmaceutical industry Biosimilar Biotechnology Drugs Biologic Drug Price Competition and Patent Term Restoration Act Generic drug Abbreviated New Drug Application Pharmaceutical sciences Pharmacology Clinical research		Generic Versions of Biologics: The Problem and a Possible Solution By Paul F. Prestia This article is reprinted with permission from The Legal Intelligencer. © 2008 ALM Properties Inc. Further duplication without permis Add to Reading List Source URL: www.ipo.org Download Document from Source Website File Size: 54,92 KB Share Document on Facebook

	Biotechnology, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xTqy - View Document
	PDF Document DocID: 1wroO - View Document
	Building A Better Mousetrap: Patenting Biotechnology In The European Community DocID: 1vr7C - View Document
	BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod DocID: 1vq6b - View Document
	Biotechnology Consultation Agency Response Letter BNF DocID: 1vpUZ - View Document